Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Sarcoma 8Rhabdomyosarcoma 8Wilms Tumor 7Malignant mesenchymal tumor 5Kidney Neoplasms 4Rhabdomyosarcoma, Embryonal 3Neuroectodermal Tumors, Primitive, Peripheral 3Rhabdomyosarcoma, Alveolar 2Hydatidiform Mole 2Gestational Trophoblastic Disease 2Stage I Mixed Cell Type Kidney Wilms Tumor 1Sarcoma, Ewing 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1Lymphoma 1Liposarcoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Hemangiosarcoma 1Hemangiopericytoma, Malignant 1Fibrosarcoma 1Desmoplastic Small Round Cell Tumor 1Choroid Plexus Neoplasms 1Choriocarcinoma 1Brain Neoplasms 1Blast Crisis 1Beckwith-Wiedemann Syndrome 1

Interventions

merphos 1etoposide phosphate 1Paclitaxel 1Methotrexate 1Leucovorin 1Ifosfamide 1Granulocyte Colony-Stimulating Factor 1Etoposide 1Dactinomycin 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Choriocarcinoma × Dactinomycin × Clear all
NCT01535053 2022-08-12

Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia

GOG Foundation

Phase 3 Completed
57 enrolled 12 charts

Choriocarcinoma, Hydatidiform Mole

Data powered by HemOnc (CC BY 4.0) Colophon âš¡